Literature DB >> 21613433

Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.

Salvador Fonseca-Coronado1, Gilberto Vaughan, Mayra Yolanda Cruz-Rivera, Juan Carlos Carpio-Pedroza, Karina Ruiz-Tovar, Juan Alberto Ruiz-Pacheco, Alejandro Escobar-Gutiérrez.   

Abstract

Several studies have identified associations between single nucleotide polymorphisms (SNPs) occurring near the interleukin-28B (IL-28B) gene and response to antiviral treatment among hepatitis C virus (HCV) patients. Here, we describe a reliable melt-mismatch amplification mutation assay (melt-MAMA) PCR-based genotyping method for IL-28B which can be used in the management of HCV patients, helping to better define the course of therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21613433      PMCID： PMC3147879          DOI： 10.1128/JCM.00877-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  Individualisation of antiviral therapy for chronic hepatitis C.

Authors:  Narci C Teoh; Geoffrey C Farrell; Henry L-Y Chan
Journal:  J Gastroenterol Hepatol       Date:  2010-07       Impact factor: 4.029

2.  Simultaneous cocirculation of both European varicella-zoster virus genotypes (E1 and E2) in Mexico city.

Authors:  Araceli Rodríguez-Castillo; Gilberto Vaughan; José Ernesto Ramírez-González; Alejandro Escobar-Gutiérrez
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.

Authors:  Maureen J Donlin; Nathan A Cannon; Rajeev Aurora; Jia Li; Abdus S Wahed; Adrian M Di Bisceglie; John E Tavis
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

4.  Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.

Authors:  Rajeev Aurora; Maureen J Donlin; Nathan A Cannon; John E Tavis
Journal:  J Clin Invest       Date:  2008-12-22       Impact factor: 14.808

5.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Authors:  Andri Rauch; Zoltán Kutalik; Patrick Descombes; Tao Cai; Julia Di Iulio; Tobias Mueller; Murielle Bochud; Manuel Battegay; Enos Bernasconi; Jan Borovicka; Sara Colombo; Andreas Cerny; Jean-François Dufour; Hansjakob Furrer; Huldrych F Günthard; Markus Heim; Bernard Hirschel; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; Andrea Witteck; Jacques S Beckmann; Thomas Berg; Sven Bergmann; Francesco Negro; Amalio Telenti; Pierre-Yves Bochud
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

7.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2009-03       Impact factor: 2.327

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962
View more
  15 in total

1.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  Allele-specific PCR for determination of IL28B genotype.

Authors:  Linda Cook; Kurt Diem; Woo Kim; John D Scott; Keith R Jerome
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping.

Authors:  Kok Siong Poon; Sherry Sze Yee Ho; Julian Wei-Tze Tang; Cui Wen Chua; Lily Chiu; Evelyn Siew-Chuan Koay
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

4.  Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals.

Authors:  Salvador Fonseca-Coronado; Alejandro Escobar-Gutiérrez; Karina Ruiz-Tovar; Mayra Yolanda Cruz-Rivera; Pilar Rivera-Osorio; Mauricio Vazquez-Pichardo; Juan Carlos Carpio-Pedroza; Juan Alberto Ruíz-Pacheco; Fernando Cazares; Gilberto Vaughan
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

5.  Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.

Authors:  Serpil Taheri; Bilgehan Aygen; Keziban Korkmaz; Orhan Yıldız; Gökmen Zararsız; Halit Canatan
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

Review 6.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  Rapid hepatitis C virus divergence among chronically infected individuals.

Authors:  Mayra Cruz-Rivera; Juan Carlos Carpio-Pedroza; Alejandro Escobar-Gutiérrez; Daniela Lozano; Arely Vergara-Castaneda; Pilar Rivera-Osorio; Armando Martinez-Guarneros; Carlos A Vazquez Chacon; Salvador Fonseca-Coronado; Gilberto Vaughan
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

8.  Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients.

Authors:  Jennifer M Reynolds; Sara A Paciga; Frances A Sanders; Craig L Hyde; A Katrina Loomis; Geoffrey I Johnston
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

9.  Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease.

Authors:  Mostafa K El-Awady; Lotiaf Mostafa; Ashraf A Tabll; Tawfeek H Abdelhafez; Noha G Bader El Din; Naglaa Zayed; Reem El Shenawy; Yasmin El Abd; Reham M Hasan; Hosam Zaghlol; Hesham El Khayat; Ashraf O Abdel Aziz
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

10.  Melt analysis of mismatch amplification mutation assays (Melt-MAMA): a functional study of a cost-effective SNP genotyping assay in bacterial models.

Authors:  Dawn N Birdsell; Talima Pearson; Erin P Price; Heidie M Hornstra; Roxanne D Nera; Nathan Stone; Jeffrey Gruendike; Emily L Kaufman; Amanda H Pettus; Audriana N Hurbon; Jordan L Buchhagen; N Jane Harms; Gvantsa Chanturia; Miklos Gyuranecz; David M Wagner; Paul S Keim
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.